Introduction
St. Louis encephalitis virus (SLEV) is an arthropod-borne, single-stranded RNA flavivirus first observed in the United States in 1933 when a major epidemic of encephalitis occurred in St. Louis, Missouri. Since that year, similar outbreaks have been reported annually in epidemic cycles in the Ohio River basin, the southern United States, and Canada. Typically, SLEV is transmitted to humans by mosquitoes that acquired the virus from infected wild birds; however, human infection seldom results in symptomatic illness. When SLEV causes disease, it is generally milder in children and young adults but more severe in elderly persons and, likely, immunocompromised persons (1).
Methods
Five patients hospitalized at our institution in 2015 were found to have neuroinvasive SLEV. Inclusion criteria for this retrospective review consisted of solid organ transplant recipients who had neuroinvasive St. Louis encephalitis (SLE) and were hospitalized from July to December 2015. Neuroinvasive SLE was defined by the presence of symptoms typical for SLEV, such as fevers, headaches, altered sensorium, cerebrospinal fluid (CSF) pleocytosis, and positive IgM antibody capture-ELISA (MAC-ELISA) with confirmatory test by plaque reduction neutralization test (PRNT) at a reference laboratory (2) (3) (4) . SLE by nucleic acid test (NAT) was not available at our laboratory and thus was not performed.
Serum and CSF specimens were sent to the Arizona Department of Health Services (ADHS) laboratory, where screening for West Nile virus (WNV) and SLEV was performed using MAC-ELISA. Test results were sensitive and accurate but not specific. Due to the cross-reactivity of IgM to several human flaviviral infections, a confirmatory test was performed to determine the specific flaviviral pathogen using PRNT at the Centers for Disease Control and Prevention (CDC) reference laboratory (3).
area had meningoencephalitis suggestive of WNV infection with inconclusive testing. Eventually, all three patients received a diagnosis of SLE.
Case 1
A 69-year-old man with end-stage renal disease secondary to diabetic nephropathy had undergone a deceased donor renal transplant 5 weeks before admission. He was hospitalized for fever, extreme fatigue, chills, and rigors that started 24 h before admission (Table 1) . His immunosuppression was reduced, and therapy was initiated with broad-spectrum antibiotics.
On hospital day 7, he had rapid deterioration of his clinical status with increasing confusion. The patient was transferred to the intensive care unit. Magnetic resonance imaging of the brain revealed diffuse cerebral atrophy. The patient had a lumbar puncture, which showed six white blood cells per cubic millimeter (WBC/mm 3 ; reference range, 0-5 WBC/mm 3 ) with 34% neutrophils and increased opening pressure (53 cm H 2 O) ( Table 1 ). Due to worsening mental status, respiratory failure, and distal muscle weakness, the patient required mechanical ventilation.
On hospital day 9, repeated lumbar puncture showed worsening pleocytosis, with 28 WBC/mm 3 , 60% neutrophils, increased protein concentration (50 mg/dL), and a normal glucose value (86 mg/dL) ( Table 1 ). The patient had increased intracranial pressure and thus required a ventriculoperitoneal shunt. He had a CSF workup for bacteria and viruses, including WNV, cytomegalovirus, human herpes virus 6, herpes simplex virus (HSV), varicella-zoster virus (VZV), and enterovirus, which were all negative. Serum WNV IgM and NAT were negative. WNV IgG was positive, and the SLEV antibody results were pending. Because of his deterioration, therapy was initiated with a combination of 14 days of 3 million units of interferon a-2b (IFN) and 5 days of 400 mg/kg per day of daily intravenous IgG (IVIG; combination IFN plus IVIG).
Within 72 h, the patient became more arousable and was able to talk, move his extremities, and follow simple commands. He received five daily doses of IVIG and a 14-day course of IFN. On day 16, the state laboratory reported MAC-ELISA positivity for both WNV and SLE in CSF and serum. Subsequently, a positive PRNT result for SLEV in CSF from the CDC confirmed the diagnosis of SLE. The patient was discharged to a rehabilitation facility. At 6 mo after discharge, he had regained all physical functions with no evidence of permanent neurologic sequelae.
Given the proximity of his SLEV infection to the organ transplant procedure, a donor investigation was conducted. It revealed that the recipient had acquired SLEV infection through a contaminated blood product transfusion 21 days after transplant (5).
Case 2
A 67-year-old man with a history of end-stage renal disease due to nodular glomerulosclerosis underwent a deceased donor kidney transplant in 2013. He was admitted with a 5-day history of fevers, rigors, headaches, confusion, and loose stools (Table 1 ). With concern about sepsis, presumably due to pyelonephritis, treatment was initiated with broad-spectrum antibiotics. Computed tomography of the head, chest, and abdomen showed no abnormalities. Coccidioides and WNV serologic testing in serum, as well as polymerase chain reaction (PCR) for Bartonella, Parvovirus, BK virus, and adenovirus, were all negative. Lumbar puncture was performed, showing 102 WBC/mm 3 with 23% neutrophils, increased protein level (108 mg/dL), and normal glucose level. Unfortunately, the patient had cardiac arrest shortly after lumbar puncture and died. Postmortem CSF analysis was negative for HSV, cytomegalovirus, VZV, enterovirus, and WNV by PCR; Cryptococcus antigen (Venereal Disease Research Laboratory test); and bacterial, fungal, and mycobacterial cultures. WNV antibodies also tested negative. A CSF specimen was sent to the ADHS laboratory. SLE was positive in MAC-ELISA and confirmed by PRNT from a reference laboratory.
Case 3
A 57-year-old man with a history of heart and kidney transplant in 2012 was admitted with a 5-day history of worsening diarrhea. Initial workup did not show a cause for his symptoms, and his mentation was at baseline. The patient had no history of mosquito bites or other exposures. Following hospital admission, he became progressively encephalopathic and was febrile to 39.1°C, with rigors and hypertension.
Lumbar puncture showed 84 WBC/mm 3 with 46% neutrophils and increased protein concentration (114 mg/dL). Immunosuppression was decreased and empirical antimicrobial therapy was initiated, targeting bacterial meningitis and herpes encephalitis. The patient's condition continued to deteriorate, requiring transfer to the intensive care unit and mechanical ventilation. CSF tests for HSV, VZV, Toxoplasma, Coccidioides, enterovirus, and WNV PCR, as well as CSF tests for WNV IgG and IgM, were negative. Serum WNV IgG and IgM tests by ELISA were negative. With no clear cause or explanation for his apparent meningoencephalitis, a CSF specimen was sent to the ADHS laboratory for arboviral diagnostics. The patient received 5 days of IVIG and 10 days of IFN as empirical therapy for possible WNV encephalitis.
Subsequent serum and CSF tests were positive for WNV IgM; testing for WNV IgG was negative. On day 21, convalescent serum was positive for WNV IgM by ELISA. The ADHS laboratory testing of CSF identified SLEV and WNV by IgM ELISA. PRNT at a reference laboratory confirmed SLEV; testing was negative for WNV. The patient recovered and was later discharged to the inpatient rehabilitation unit. At his 6-mo follow-up visit, he showed marked improvement, with dysarthria as the only sequela.
Discussion
Central nervous system infections pose a major diagnostic and management challenge for transplant recipients. Infectious etiologic factors are influenced by the degree of immunosuppression, epidemiological exposures, reactivation of latent infection, and donor-derived infections (6,7).
SLEV is a single-stranded RNA flavivirus that belongs to the Japanese encephalitis complex, sharing close antigenic relationships with Japanese encephalitis, WNV, and Murray Valley encephalitis virus. It also is related to dengue and yellow fever viruses (8) .
SLEV was discovered in 1933, when a major epidemic with 1350 cases of what was known then as encephalitis lethargica occurred between August and October in St. Louis, Missouri, and neighboring counties (9) . After extensive work, clinicians located a virus from suspensions of brain specimens of deceased patients after inoculation into white mice and rhesus monkeys (10) . The principal vector for SLEV is the Culex mosquito species (3). Humans and other mammals are dead-end hosts of a mosquito-bird-mosquito cycle.
The number of reported cases of SLEV infection fluctuates annually because of epidemic cycles (3). The virus can be found in the Western Hemisphere, but epidemics typically occur in the Ohio River-Mississippi River basin, Florida, Texas, and, less frequently, in the western United States (3) (Figure 1 ). In southern states such as Florida, cases of SLEV can be found year round, but in more temperate areas of the United States and Canada, cases occur during summer and fall (3). After 1999, with the coincidental appearance of WNV, incidence of SLEV decreased notably. Displacement of SLEV by WNV was due to efficient transmission and cross-immunity within avian hosts (11) .
During the 2010-2014 season, only one case was reported to the ADHS. By December 2015, however, 19 In the general U.S. population, <1% of all SLEV infections lead to symptomatic infection ranging from febrile illness and headache to aseptic meningitis or encephalitis (13) . When disease ensues, its severity is typically associated with age. In a young and healthy population, SLEV infections present as minimally symptomatic, associated with only fevers and headaches or aseptic meningitis. Elderly persons bear the challenge of greater morbidity, a higher mortality rate, and prolonged recovery. According to the CDC, almost 90% of encephalitis and coma in severe SLEV infection cases occur in persons aged >60 years (1). Unfortunately, the prevalence, prognosis, and treatment options for SLEV infection in immunocompromised hosts such as transplant recipients are largely unknown (3).
Laboratory evaluation of CSF in SLEV infection reveals lymphocytosis, elevated protein level, and a normal glucose value (14) . Unfortunately, these findings are not specific to SLEV, and viral cultures are difficult to obtain; therefore, serologic testing is the preferred method for SLEV diagnosis. Because of the antigenic cross-reactions with other flaviviruses and particularly WNV and Japanese encephalitis virus (15), further confirmatory testing is required with PRNT, performed at a reference laboratory.
Three solid organ transplant recipients were hospitalized at our institution with confirmed neuroinvasive SLEV infection during the 2015 mosquito season. These patients presented to the hospital during June through September. All patients had fever. Other common presenting symptoms were rigors, diarrhea, and headache.
In all three patients, a neuroinvasive infection following hospitalization was suspected, and this suspicion resulted in CSF examination. CSF findings are documented in Table 1 . One patient died, whereas the two other patients survived and required prolonged hospitalization. Recovery of one patient was complete without sequelae; the other patient had residual dysarthria. Of the two surviving patients, one patient received 3 million units of IFN for 14 days and IVIG 400 mg/kg daily for 5 days; the other patient received 3 million units of IFN for 10 days and IVIG 400 mg/kg daily for 6 days. (The third patient died 3 days after admission, before definitive diagnosis or initiation of the investigational therapy.) We observed clinical improvement within 72 h and neurologic improvement within a week after initiation of the combination therapy (Table 1) .
At present, no treatment has received U.S. Food and Drug Administration approval for SLEV or the more common flaviviruses such as WNV. A pilot study by Rahal et al (16) in 2004 showed that early initiation of IFN reduced the severity and complications of SLEV meningoencephalitis.
In contrast to the study by Rahal et al (16) , the initiation of therapy was delayed in two of our cases-by 8 days and 20 days, respectively-because of diagnostic uncertainty. Even with delayed administration, treatment with IFN plus IVIG was associated with clinical improvement in both patients. Whether this is a consequence of treatment or reduction in immunosuppression or the natural history of disease is unknown.
Treatment approaches to closely related flaviviral infection such as WNV have also used IVIG and IFN. Case reports of immunosuppressed patients taking high-titer IVIG have shown some benefit (17) (18) (19) . In addition, in the murine model, the use of high-titer WNV IVIG from selected Israeli donors, as well as commercial preparations of IVIG, provided protection to infected mice (20) (21) (22) , particularly early in the disease. It is unknown whether standard IVIG preparations contain significant quantities of SLEV-specific immunoglobulin.
Our IVIG preparations were not tested for specific antibodies.
The use of IFN has also been evaluated in flavivirus infections other than SLEV. IFN is currently approved for the treatment of hepatitis C virus (a flavivirus). For WNV infection, literature is scarce regarding the use of IFN. An in vitro study showed inhibition of viral cytotoxicity to cultured cells when IFN treatment was applied before or after infection; therefore, it is speculated to be protective and therapeutic (23) . In WNV-infected mice, there seems to be a mortality benefit (24) . In addition, three case reports (N = 5) showed improvement after initiation of IFN, although it is unclear whether this outcome was secondary to the normal disease course or a true effect, considering that one patient received IFN 3 weeks after the onset of disease (25) (26) (27) .
Results of this retrospective case series suggest increased morbidity and mortality rates among transplant recipients and a potential benefit of IFN plus IVIG treatment of patients with suspected SLEV infection; however, the small number of patients treated, the uncertainty of SLEV-specific antibody in the general population, and the lack of randomization preclude widespread support of empirical use of IFN plus IVIG. Future prospective trials will likely shed light on this matter.
Novel approaches to central nervous system viral infection with humanized monoclonal antibodies against WNV and Venezuela equine encephalitis have been tested successfully in murine models (28, 29) . No randomized human trials have been performed, and at present, they are purely investigational.
In summary, SLEV is an uncommon viral infection (3) that is often asymptomatic. Nonetheless, it carries an increased mortality rate in elderly persons (30) and an unknown mortality rate in the immunosuppressed host. There are no distinguishing clinical features of SLEV neuroinvasive infection, and its diagnostic consideration is further challenged by the lack of a readily available commercial test. Confirmation at a reference laboratory is required, hindering the clinician's ability to diagnose SLEV infection in a timely manner. Unless contraindicated, use of IFN plus IVIG should be considered for immunosuppressed patients with neuroinvasive SLEV infection. Transplant centers must exercise caution when accepting deceased donors with meningitis or encephalitis because disease transmission to recipients is a serious concern (7). Guidelines have been released by the Organ Procurement and Transplantation Network for recognizing central nervous system infections in potential deceased organ donors (31) .
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